Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor) ; volume:14 ; number:2 ; day:9 ; month:2 ; year:2024 ; pages:441-451 ; date:2.2024
Dermatology and therapy ; 14, Heft 2 (9.2.2024), 441-451, 2.2024
- Creator
-
Gooderham, Melinda
Vender, Ronald
Crowley, Jeffrey
Hong, H. Chih-Ho
Feely, Meghan
Garrelts, Alyssa
See, Kyoungah
Konicek, Bruce
Green, Lawrence
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-023-01075-y
- URN
-
urn:nbn:de:101:1-2404301318266.851812880006
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gooderham, Melinda
- Vender, Ronald
- Crowley, Jeffrey
- Hong, H. Chih-Ho
- Feely, Meghan
- Garrelts, Alyssa
- See, Kyoungah
- Konicek, Bruce
- Green, Lawrence
- SpringerLink (Online service)
Other Objects (12)
Ixekizumab : Interleukin-17A-Inhibitor zur zielgerichteten Therapie der Psoriasis-Arthritis nach DMARD
Ixekizumab : Interleukin-17A-Inhibitor zur zielgerichteten Therapie der Psoriasis-Arthritis nach DMARD
Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
Ixekizumab : ein zielgerichteter Interleukin-17A-Inhibitor bei Erwachsenen mit mitttelschwerer bis schwerer Plaque-Psoriasis
Interleukin-2 [Interleukin] - Isolierung, Charakterisierung und Expressionsstudien des murinen Interleukin-2-Gens [Interleukin-Gens]
Bestimmung der Zytokine Interleukin-1α [Interleukin-1-alpha], Interleukin-1β [Interleukin-1-beta], Interleukin-2, Interleukin-3 und Interleukin-4 im Vaginalsekret bei Frauen mit bakterieller Dysbiose
Bestimmung der Zytokine Interleukin-1α [Interleukin-1-alpha], Interleukin-1β [Interleukin-1-beta], Interleukin-2, Interleukin-3 und Interleukin-4 im Vaginalsekret bei Frauen mit bakterieller Dysbiose
Nachweis von Interleukin-1α [Interleukin-1-Alpha], Interleukin-1β [Interleukin-1-Beta], Interleukin-5 und Interleukin-10 im vaginalen Abstrich von gesunden Frauen
Interleukin-1α [Interleukin-1alpha], löslicher Interleukin-2-Rezeptor und Interleukin-8 bei entzündlichen interstitiellen Lungenkrankheiten
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
Ixekizumab : Interleukin-17A-Inhibitor zur zielgerichteten Therapie der Psoriasis-Arthritis nach DMARD
Ixekizumab : Interleukin-17A-Inhibitor zur zielgerichteten Therapie der Psoriasis-Arthritis nach DMARD
Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
Ixekizumab : ein zielgerichteter Interleukin-17A-Inhibitor bei Erwachsenen mit mitttelschwerer bis schwerer Plaque-Psoriasis
Interleukin-2 [Interleukin] - Isolierung, Charakterisierung und Expressionsstudien des murinen Interleukin-2-Gens [Interleukin-Gens]
Bestimmung der Zytokine Interleukin-1α [Interleukin-1-alpha], Interleukin-1β [Interleukin-1-beta], Interleukin-2, Interleukin-3 und Interleukin-4 im Vaginalsekret bei Frauen mit bakterieller Dysbiose
Bestimmung der Zytokine Interleukin-1α [Interleukin-1-alpha], Interleukin-1β [Interleukin-1-beta], Interleukin-2, Interleukin-3 und Interleukin-4 im Vaginalsekret bei Frauen mit bakterieller Dysbiose
Nachweis von Interleukin-1α [Interleukin-1-Alpha], Interleukin-1β [Interleukin-1-Beta], Interleukin-5 und Interleukin-10 im vaginalen Abstrich von gesunden Frauen
Interleukin-1α [Interleukin-1alpha], löslicher Interleukin-2-Rezeptor und Interleukin-8 bei entzündlichen interstitiellen Lungenkrankheiten
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
Ixekizumab : Interleukin-17A-Inhibitor zur zielgerichteten Therapie der Psoriasis-Arthritis nach DMARD
Ixekizumab : Interleukin-17A-Inhibitor zur zielgerichteten Therapie der Psoriasis-Arthritis nach DMARD
Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
Ixekizumab : ein zielgerichteter Interleukin-17A-Inhibitor bei Erwachsenen mit mitttelschwerer bis schwerer Plaque-Psoriasis
Interleukin-2 [Interleukin] - Isolierung, Charakterisierung und Expressionsstudien des murinen Interleukin-2-Gens [Interleukin-Gens]
Bestimmung der Zytokine Interleukin-1α [Interleukin-1-alpha], Interleukin-1β [Interleukin-1-beta], Interleukin-2, Interleukin-3 und Interleukin-4 im Vaginalsekret bei Frauen mit bakterieller Dysbiose
Bestimmung der Zytokine Interleukin-1α [Interleukin-1-alpha], Interleukin-1β [Interleukin-1-beta], Interleukin-2, Interleukin-3 und Interleukin-4 im Vaginalsekret bei Frauen mit bakterieller Dysbiose
Nachweis von Interleukin-1α [Interleukin-1-Alpha], Interleukin-1β [Interleukin-1-Beta], Interleukin-5 und Interleukin-10 im vaginalen Abstrich von gesunden Frauen
Interleukin-1α [Interleukin-1alpha], löslicher Interleukin-2-Rezeptor und Interleukin-8 bei entzündlichen interstitiellen Lungenkrankheiten